Synbody Biotechnology

About:

SBI is a biotechnology company leveraging a platform to develop molecules in the therapeutic, diagnostic and proteomic technology fields.

Website: http://www.synbodybio.com

Description:

Synbody Biotechnology (SBI) is a start-up biotechnology company based on a powerful synthetic antibody, or "Synbody," technology recently discovered at Arizona State University. Synbodies revolutionize the field of high affinity, high specificity therapeutic agents by creating antibody-like function from small purely synthetic peptides. It is SBI's mission to leverage the Synbody technology to create a pipeline of superior human therapeutics across multiple therapeutic areas. SBI seeks to realize the opportunity for synbodies as human therapeutics through a combined strategy comprising corporate partnerships, out-licensing agreements and in-house development.

Total Funding Amount:

$750000

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Farmington, Connecticut, United States

Founded Date:

2010-01-01

Contact Email:

contact(AT)synbodybio.com

Founders:

Paul Hallenbeck

Number of Employees:

1-10

Last Funding Date:

2012-03-13

IPO Status:

Private

Industries:

© 2025 bioDAO.ai